That is true. I have been speaking to a lot of funds that are large enough to be able to afford to have a biotech analysts, yet few do. When I get to talk to those that do have one, the quality of conversation is on another level - instead of talking about short term catalysts of the SP, I get into the nitty-gritty of our development and commercialisation strategy. These investors really get what we are trying to do and can see the value, not just can how they make a quick buck to boost their quarterly numbers.
RAC - Charts & Price Action, page-333
-
- There are more pages in this discussion • 21,151 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.71 |
Change
0.010(0.59%) |
Mkt cap ! $291.1M | |||
| Open | High | Low | Value | Volume |
| $1.74 | $1.75 | $1.70 | $226.9K | 131.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 9599 | $1.71 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.74 | 4886 | 1 |
View Market Depth
| Last trade - 16.10pm 25/06/2024 (20 minute delay) ? |
| RAC (ASX) Chart |